Last reviewed · How we verify

NCT05231915: HOXB13_Mart

Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique

Completed NA Last updated 31 March 2026
What this trial tests

NA trial testing HOXB13 c.853delT mutation in Prostate Cancer in 465 participants. Completed in 9 March 2025.

Timeline
9 April 2021
Primary endpoint
27 November 2024
9 March 2025

Quick facts

Lead sponsorUniversity Hospital Center of Martinique
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment465
Start date9 April 2021
Primary completion27 November 2024
Estimated completion9 March 2025
Sites1 location across Martinique

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Center of Martinique

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In Martinique, prostate cancer incidence rates are nowadays among the highest worldwide with a high incidence of early-onset and familial forms. We identified a rare heterozygous germline variant c.853delT (p.Ter285Lysfs) rs77179853, reported only among patients of African ancestry with a minor allele frequency of 3.2%. We search to estimate the prevalence of this variant in a sample of prevalent prostate cancer cases managed in urology consultation in Martinique .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

Other University Hospital Center of Martinique trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05231915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing